results from its study—a randomized control trial of 600 participants with prediabetes—that show its virtual diabetes prevention platform is more effective than a basic educational program offered by the University of Nebraska in preventing diabetes. After 12 months of using Omada's digital plan—which includes health coaching and virtual consultations with physicians—participants noted an average 0.23% reduction in A1C , while the educational group reduced their A1C by just 0.15%.
Clear cases of clinical effectiveness and positive ROI will be key in luring payers to forge tie-ups with DTx firms: reported This growing body of evidence highlights Omada's potential to curb long-term chronic disease costs—an attractive proposition for payers. Chronic conditions like diabetes and hypertension make up of the US' annual $3.5 trillion in healthcare spending—steep costs payers will be looking to stave off their share of.
But ultimately, DTx firms will need to win over doctors, who'll be recommending these tools to their patients and engaging with them in treatment plans. US providers are already dealing with admin driving significant rates of burnout—which is only further compounded by the lack of data interoperability among hospitals.